• Otofarma reported 6,172 hearing aids sold in H1 2026, up 4% from 5,925 a year earlier, with a shift toward higher-end products.
• Pharmacy channel sales reached 5,470 units, up 2%; direct channel rose to 567 units, up 77%.
• ASL channel slipped to 135 units, down 46%, citing administrative delays.
• Affiliate pharmacies increased to 4,689 from 4,462 at end-2025; active pharmacies rose to 1,565 from 1,440 a year earlier.
• Teleaudiology visits climbed to 4,506 from 3,774 (+19%); specialist telemedicine visits jumped to 2,903 from 523.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Otofarma S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20343-20-2026_TELEBORSA.pdf), on July 23, 2026, and is solely responsible for the information contained therein.